Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

News >

Emerging Agents Offer New Hope in HCC

Brandon Scalea
Published: Wednesday, Aug 29, 2018

Amit G. Singal, MD
Amit G. Singal, MD
Hepatocellular carcinoma (HCC), a disease that accounts for approximately 90% of liver cancers worldwide, is often diagnosed in the advanced stage where treatment options have been limited, according to Amit G. Singal, MD. However, recent data have led to first- and second-line changes in the landscape.

For example, in August 2018, the FDA approved lenvatinib (Lenvima) as a first-line treatment for patients with unresectable hepatocellular carcinoma, based on data from the phase III REFLECT trial.

The trial showed that lenvatinib was noninferior to sorafenib (Nexavar) in the frontline setting, which was the established first-line standard of care. Median overall survival (OS) was 13.6 months on the lenvatinib arm compared with 12.3 months for those who received sorafenib.1 In terms of progression-free survival (PFS), lenvatinib and sorafenib were associated with a median PFS of 7.4 months and 3.7 months, respectively. Toxicity data were comparable in the 2 arms.

More recently, the REACH-2 trial highlighted ramucirumab (Cyramza) as a promising second-line therapy; high levels of alpha-fetoprotein (AFP) also emerged as a potential biomarker predictive of response to this treatment. This randomized, placebo-controlled, phase III study compared ramucirumab with placebo in patients with advanced HCC following first-line sorafenib.

Median OS was 8.5 months in the ramucirumab arm versus 7.3 for placebo. PFS was significantly improved for patients treated with ramucirumab at 2.8 versus 1.6 months, respectively. Moreover, ramucirumab reduced the risk of death by 29% for patients with high AFP (≥400 ng/mL).2

In an interview with OncLive® at the 2018 State of the Science Summit™ on Gastrointestinal Cancers, Singal, associate professor and medical director of the Liver Tumor Program and clinical chief of Hepatology at UT Southwestern Medical Center, discussed the evolving armamentarium of treatment options for patients with HCC.

OncLive: What were the key points from your presentation?

Singal: HCC is a cancer that is actually increasing in incidence and mortality in the United States. While we are making great progress in other cancers, the relevance and unmet need of HCC is rapidly increasing. Over the last decade, the HCC incidence has more than doubled, according to some data we have. One of the things we talked about is some of the interesting and exciting progress made in terms of treatment, particularly in advanced HCC management. This is important because most HCC cases occur in the advanced stage when they aren't eligible for curative therapies.

The progress we have made with systemic therapies will benefit patients in terms of their survival. The first systemic therapy we had for HCC was approved about 1 decade ago. When that came out, people were excitedly saying, "This is the first step, but we anticipate many more therapies coming out over the next several years."

In the years that followed, all we had was negative trial after negative trial, and then more negative trials. Then, in the past year, we had an explosion of positive trials, both in the frontline and second-line settings. We had the REFLECT trial, which was a positive study comparing lenvatinib with sorafenib. It showed that lenvatinib has noninferior survival to sorafenib. Now we have first-line treatment options for patients with advanced HCC.

Furthermore, we finally have treatment options for second-line therapy. This means that if patients fail on lenvatinib or sorafenib, or if they progress, we have therapies we can use for those patients as well. We've had the RESORCE trial [with regorafenib] and the CheckMate-040 trial [with nivolumab]; both are positive and have FDA approval for these agents. Finally, I briefly touched on the CELESTIAL and REACH-2 studies [of cabozantinib (Cabometyx) and ramucirumab, respectively], which are positive trials in the second-line setting but are awaiting FDA approval.

With these recent advancements and FDA approvals, how important is sequencing?

This is going to be the biggest question. With all these tools in your toolbox, how do you decide which agents to use and when to switch? We've made progress in terms of making these agents available. The next step is how to determine the best agent to use first, and when we should switch. When do you declare that this patient is no longer responding?




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x